

Supplementary Table 1. The proportion of subjects (M=male; F=female) positive for nucleoprotein (N) and spike proteins (SFL and RBD) IgG antibodies and the proportion of subjects positive and low positive (borderline) for neutralizing antibodies (NAb) twelve months after infection against four SARS-CoV-2 virus strains (n=78).

Disease severity	Age	Gender	n	IgG positivity%			MNT positivity (%) <i>MNT borderline (%)</i>			
				N-IgG	S-IgG (RBD)	S-IgG (SFL)	NAb wt	NAb Alpha	NAb Beta	NAb Delta
Severe	<60y	M+F	22	18/22 (82)	22/22 (100)	22/22 (100)	22/22 (100)	21/22 (95)	14/22 (64) 2/22 (9)	18/22 (82) 2/22 (9)
		M	12	10/12 (83)	12/12 (100)	12/12 (100)	12/12 (100)	12/12 (100)	8/12 (67)	10/12 (83) 2/12 (17)
		F	10	8/10 (80)	10/10 (100)	10/10 (100)	10/10 (100)	9/10 (90)	6/10 (60) 2/10 (20)	8/10 (80)
	≥60v	M+F	17	14/17 (82)	17/17 (100)	17/17 (100)	17/17 (100)	17/17 (100)	11/17 (65) 2/17 (12)	16/17 (94) 1/17 (6)
		M	8	6/8 (75)	8/8 (100)	8/8 (100)	8/8 (100)	8/8 (100)	5/8 (63) 2/8 (25)	8/8 (100)
		F	9	8/9 (89)	9/9 (100)	9/9 (100)	9/9 (100)	9/9 (100)	6/9 (67)	8/9 (89) 1/9 (11)
Mild	<60v	M+F	22	11/22 (50)	22/22 (100)	22/22 (100)	22/22 (100)	16/22 (73) 2/22 (9)	9/22 (41) 1/22 (5)	8/22 (37) 3/22 (14)
		M	12	6/12 (50)	12/12 (100)	12/12 (100)	12/12 (100)	6/12 (50) 2/12 (17)	3/12 (25) 1/12 (8)	2/12 (17) 2/12 (17)
		F	10	5/10 (50)	10/10 (100)	10/10 (100)	10/10 (100)	10/10 (100)	6/10 (60)	6/10 (60) 1/10 (10)
	≥60v	M+F	17	9/17 (53)	17/17 (100)	17/17 (100)	16/17 (94) 1/17 (6)	11/17 (65) 1/17 (6)	8/17 (47)	10/17 (59) 1/17 (6)
		M	8	6/8 (75)	8/8 (100)	8/8 (100)	7/8 (88) 1/8 (13)	3/8 (38) 1/8 (13)	2/8 (25)	3/8 (38) 1/8 (13)
		F	9	3/9 (33)	9/9 (100)	9/9 (100)	9/9 (100)	8/9 (89)	6/9 (67)	7/9 (78)